Related Experiment Video

Updated: May 28, 2026

Formulation and Characterization of Bioactive Agent Containing Nanodisks
07:58

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Published on: March 17, 2023

Emerging therapeutic strategies to enhance HDL function

Santiago Redondo1, José Martínez-González, Concha Urraca

  • 1Department of Pharmacology, School of Medicine, Universidad Complutense de Madrid, Spain. santiredondo@hotmail.com

Lipids in Health and Disease
|October 12, 2011
PubMed

Insights

High-density lipoproteins (HDL) show a strong inverse correlation with cardiovascular disease (CVD). Novel therapies targeting HDL function and reverse cholesterol transport (RCT) offer new hope for treating CVD.

Area of Science:

  • Cardiovascular Science
  • Lipid Metabolism
  • Pharmacology

Background:

  • Epidemiologic studies reveal a significant inverse correlation between plasma high-density lipoprotein (HDL) levels and cardiovascular disease (CVD) risk.
  • High-density lipoproteins (HDL) are crucial for cardioprotection, primarily through the mechanism of reverse cholesterol transport (RCT).
  • Recent advancements in understanding HDL biology and RCT have paved the way for developing novel therapeutic agents.

Purpose of the Study:

  • To explore the potential of agents designed to enhance HDL function.
  • To investigate the role of new therapies in promoting atherosclerosis regression.
  • To highlight promising therapeutic strategies for cardiovascular disease treatment.

Main Methods:

  • Review of epidemiologic data linking HDL levels to CVD.
  • Analysis of the biological mechanisms of HDL-mediated reverse cholesterol transport (RCT).
  • Evaluation of emerging therapeutic agents, including apo-AI analogs and CETP inhibitors (dalcetrapib, anacetrapib).

Main Results:

  • Strong evidence supports an inverse relationship between HDL plasma levels and CVD incidence.
  • Reverse cholesterol transport (RCT) is identified as a key cardioprotective pathway mediated by HDL.
  • Apo-AI analogs and CETP inhibitors like dalcetrapib and anacetrapib show promise in increasing HDL function and potentially regressing atherosclerosis.

Conclusions:

  • Novel agents targeting HDL function and RCT represent a promising frontier in cardiovascular disease management.
  • Therapeutic strategies aimed at enhancing HDL functionality hold significant potential for atherosclerosis regression.
  • Further research into apo-AI analogs and CETP inhibitors is warranted for their clinical application in CVD treatment.

More Related Videos

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Bioavailability Enhancement: Drug Permeability Enhancement01:27

Bioavailability Enhancement: Drug Permeability Enhancement

After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...